Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2023

09-07-2022 | Special Section: Methodologies for Meaningful Change

How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales

Auteurs: Kim Cocks, Jacqueline Buchanan

Gepubliceerd in: Quality of Life Research | Uitgave 5/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The recommended method for establishing a meaningful threshold for individual changes in patient-reported outcome (PRO) scores over time uses an anchor-based method. The patients assess their perceived level of change and this is used to define a threshold on the PRO score which may be considered meaningful to the patient. In practice, such an anchor may not be available. In the absence of alternative information often the meaningful change threshold for assessing between-group differences, the minimally important difference, is used to define meaningful change at the individual level too. This paper will highlight the issues with this, especially where the underlying measurement scale is not continuous.

Methods

Using the EORTC QLQ-C30 as an example, plausible score increments (“state changes”) are calculated for each subscale highlighting why commonly used thresholds may be misleading, including leading to sensitivity analyses that are inadvertently testing the same underlying threshold.

Results

The minimal possible individual score change varies across subscales; 6.7 for Physical Functioning, 8.3 for Global Health Scale and Emotional Functioning, 11.1 for fatigue, 16.7 for role functioning, cognitive functioning, social functioning, nausea and vomiting, pain and 33.3 for single items.

Conclusions

The determination of meaningful change for an individual patient requires input from the patients but being mindful of the underlying scale ensures that these thresholds are also guided by what is a plausible change for patients to achieve on the scale.
Literatuur
1.
go back to reference Food and Durg Administration. (2009). Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133. Food and Durg Administration. (2009). Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.
2.
go back to reference Anota, A., Hamidou, Z., Paget-Bailly, S., et al. (2015). Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research, 24(1), 5–18.CrossRefPubMed Anota, A., Hamidou, Z., Paget-Bailly, S., et al. (2015). Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research, 24(1), 5–18.CrossRefPubMed
3.
go back to reference Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415.CrossRefPubMed Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415.CrossRefPubMed
4.
go back to reference Wyrwich, K. W., Tierney, W. M., Babu, A. N., Kroenke, K., & Wolinsky, F. D. (2005). A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research, 40(2), 577–592.CrossRefPubMedPubMedCentral Wyrwich, K. W., Tierney, W. M., Babu, A. N., Kroenke, K., & Wolinsky, F. D. (2005). A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research, 40(2), 577–592.CrossRefPubMedPubMedCentral
5.
go back to reference Beckerman, H., Roebroeck, M. E., Lankhorst, G. J., Becher, J. G., Bezemer, P. D., & Verbeek, A. L. (2001). Smallest real difference, a link between reproducibility and responsiveness. Quality of Life Research., 10(7), 571–578.CrossRefPubMed Beckerman, H., Roebroeck, M. E., Lankhorst, G. J., Becher, J. G., Bezemer, P. D., & Verbeek, A. L. (2001). Smallest real difference, a link between reproducibility and responsiveness. Quality of Life Research., 10(7), 571–578.CrossRefPubMed
6.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute., 85(5), 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute., 85(5), 365–376.CrossRefPubMed
7.
go back to reference Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). European Organization for Research and Treatment of Cancer. Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). European Organization for Research and Treatment of Cancer.
8.
go back to reference Lenz, H.-J., Argiles, G., Yoshino, T., et al. (2019). Health-related quality of life in the Phase III LUME-Colon 1 study: Comparison and interpretation of results from EORTC QLQ-C30 analyses. Clinical Colorectal Cancer, 18, 269–279.CrossRefPubMedPubMedCentral Lenz, H.-J., Argiles, G., Yoshino, T., et al. (2019). Health-related quality of life in the Phase III LUME-Colon 1 study: Comparison and interpretation of results from EORTC QLQ-C30 analyses. Clinical Colorectal Cancer, 18, 269–279.CrossRefPubMedPubMedCentral
9.
go back to reference Anota, A., Mouillet, G., Trouilloud, I., et al. (2015). Sequential FOLFIRI 3+ Gemcitabine improves health-related quality of life deterioration-free survival of patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. PLoS ONE, 10(5), e0125350.CrossRefPubMedPubMedCentral Anota, A., Mouillet, G., Trouilloud, I., et al. (2015). Sequential FOLFIRI 3+ Gemcitabine improves health-related quality of life deterioration-free survival of patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. PLoS ONE, 10(5), e0125350.CrossRefPubMedPubMedCentral
10.
go back to reference Stockler, M. R., Hilpert, F., Friedlander, M., et al. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology., 32(13), 1309.CrossRefPubMedPubMedCentral Stockler, M. R., Hilpert, F., Friedlander, M., et al. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology., 32(13), 1309.CrossRefPubMedPubMedCentral
11.
go back to reference Harrison, C. N., Mesa, R. A., Kiladjian, J. J., et al. (2013). Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 162(2), 229–239.CrossRefPubMed Harrison, C. N., Mesa, R. A., Kiladjian, J. J., et al. (2013). Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 162(2), 229–239.CrossRefPubMed
12.
go back to reference Bonnetain, F., Dahan, L., Maillard, E., et al. (2010). Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer., 46(15), 2753–2762.CrossRefPubMed Bonnetain, F., Dahan, L., Maillard, E., et al. (2010). Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer., 46(15), 2753–2762.CrossRefPubMed
13.
go back to reference Eisenhardt, A., Schneider, T., Scheithe, K., Colling, C., & Heidenreich, A. (2015). Health-related quality of life in patients with advanced prostate cancer undergoing treatment with TRIPTOrelin Pamoate SIX month formulation: Results of the non-interventional TRIPTOSIX study. Journal of Clinical Oncology, 33, 287.CrossRef Eisenhardt, A., Schneider, T., Scheithe, K., Colling, C., & Heidenreich, A. (2015). Health-related quality of life in patients with advanced prostate cancer undergoing treatment with TRIPTOrelin Pamoate SIX month formulation: Results of the non-interventional TRIPTOSIX study. Journal of Clinical Oncology, 33, 287.CrossRef
14.
go back to reference Osoba, D., Bezjak, A., Brundage, M., et al. (2005). Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer., 41(2), 280–287.CrossRefPubMed Osoba, D., Bezjak, A., Brundage, M., et al. (2005). Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer., 41(2), 280–287.CrossRefPubMed
15.
go back to reference Osoba, D., Bezjak, A., Brundage, M., Pater, J., National Cancer Institute of Canada Clinical Trials Group. (2007). Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value Health., 10, S138–S145.CrossRefPubMed Osoba, D., Bezjak, A., Brundage, M., Pater, J., National Cancer Institute of Canada Clinical Trials Group. (2007). Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value Health., 10, S138–S145.CrossRefPubMed
16.
go back to reference Brundage, M., Osoba, D., Bezjak, A., Tu, D., Palmer, M., & Pater, J. (2007). Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology., 25(32), 5078–5081.CrossRefPubMed Brundage, M., Osoba, D., Bezjak, A., Tu, D., Palmer, M., & Pater, J. (2007). Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology., 25(32), 5078–5081.CrossRefPubMed
17.
go back to reference Kawahara, T., Shimozuma, K., Shiroiwa, T., et al. (2018). Patient-reported outcome results from the open-label randomized phase III select bc trial evaluating first-line s-1 therapy for metastatic breast cancer. Oncology, 94(2), 107–115.CrossRefPubMed Kawahara, T., Shimozuma, K., Shiroiwa, T., et al. (2018). Patient-reported outcome results from the open-label randomized phase III select bc trial evaluating first-line s-1 therapy for metastatic breast cancer. Oncology, 94(2), 107–115.CrossRefPubMed
18.
go back to reference Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology., 29(1), 89–96.CrossRefPubMed Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology., 29(1), 89–96.CrossRefPubMed
Metagegevens
Titel
How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales
Auteurs
Kim Cocks
Jacqueline Buchanan
Publicatiedatum
09-07-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03181-4

Andere artikelen Uitgave 5/2023

Quality of Life Research 5/2023 Naar de uitgave